Portland, OR -- (SBWIRE) -- 09/19/2017 -- Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.
Access the full summarty at: https://www.alliedmarketresearch.com/recombinant-chinese-hamster-ovary-cell-CHO-hepatitis-b-vaccine-market
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3858
The key players profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India, and Johnson & Johnson.
-The study provides an in-depth analysis of the global recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine market with current trends and future estimations to elucidate the imminent investment pockets.
-It presents a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities.
-Extensive analysis of the market by type assists to understand the various forms of recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccines available.
-Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
Early buyers will receive 20% customization on this report